Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by uncontrolled complement activation and leading to thrombocytopenia, microangiopathic hemolysis acute kidney injury. Eculizumab, humanized monoclonal antibody that inhibits the cleavage protein C5, effectively reverses laboratory evidence TMA improves function in most patients with aHUS. Heredi...